Awakn Life Sciences Corp. (AWKN.NE)
Chart Events
Performance Outlook
| Previous Close | 0.3300 |
| Open | 0.3400 |
| Bid | 0.3200 x N/A |
| Ask | 0.3600 x N/A |
| Day's Range | 0.3300 - 0.3400 |
| 52 Week Range | 0.2500 - 2.0500 |
| Volume | |
| Avg. Volume | 20,807 |
| Market Cap | 11.042M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6460 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.75 |
- Newsfile
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine a
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector 22nd Century announced partnerships with Core-Mark and Eby-Brown, two of the largest U.S. convenience store distributors. Scotts Miracle-Gro announced timing for Q1 financial results and conference call. Tilray’s revenue declines as net losses increase; if cannabis sales continue to be slow, the company may switch to fruit and beer sales. Key […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
- Newsfile
Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth
And continued successful execution of R&D and Commercialization strategies Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022. All results are reported under
